# Research Study to Compare a New Medicine Fast-acting Insulin Aspart to Another Medicine Insulin Aspart in Chinese People With Diabetes

Study · id `cardio:ct-nct04588259` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04588259](<https://clinicaltrials.gov/study/NCT04588259>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04588259

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 331 participants.

## Technical summary

Registry record NCT04588259. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-09 (actual); primary completion 2022-07-05 (actual). Results posted on 2024-03-20.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 331 participants (enrolled count; ClinicalTrials.gov record NCT04588259, source copy `cardio:ctgov-nct04588259-2025-12-04`, retrieved 2026-10-26)
- Started: 2020-10-09 (actual) (ClinicalTrials.gov record NCT04588259, source copy `cardio:ctgov-nct04588259-2025-12-04`, retrieved 2026-10-26)
- Primary completion: 2022-07-05 (actual) (ClinicalTrials.gov record NCT04588259, source copy `cardio:ctgov-nct04588259-2025-12-04`, retrieved 2026-10-26)
- Completion: 2022-08-05 (actual) (ClinicalTrials.gov record NCT04588259, source copy `cardio:ctgov-nct04588259-2025-12-04`, retrieved 2026-10-26)
- Results first posted: 2024-03-20 (ClinicalTrials.gov record NCT04588259, source copy `cardio:ctgov-nct04588259-2025-12-04`, retrieved 2026-10-26)
- Countries: China; Hong Kong SAR China (ClinicalTrials.gov record NCT04588259, source copy `cardio:ctgov-nct04588259-2025-12-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04588259-2025-12-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
- Condition: Diabetes Mellitus, Type 1
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Faster aspart
- Intervention (Drug): Insulin aspart
- Intervention (Drug): Insulin degludec
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 2bc0ba240a4cca66c62448a973d897fbce2d70f5e1ea4f00b909a9f9a2b0f833
Last substantive edit: 2026-10-30
Evidence last checked: Not recorded
